Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its
prevalence is rapidly increasing due to extended lifespans. Among the increasing number of …

Dysregulation of lipid metabolism has emerged as a central component of many
neurodegenerative diseases. Variants of the lipid transport protein, apolipoprotein E …

Microglial involvement in Alzheimer's disease (AD) pathology has emerged as a risk-
determining pathogenic event. While apolipoprotein E (APOE) is known to modify AD risk, it …

Alzheimer's disease (AD) is caused by a complex interaction between genetic and
environmental factors. However, how the role of peripheral organ changes in response to …

The human gastrointestinal tract is populated with a diverse microbial community. The vast
genetic and metabolic potential of the gut microbiome underpins its ubiquity in nearly every …

Alzheimer's disease (AD) is a frequent and disabling neurodegenerative disorder, in which
astrocytes participate in several pathophysiological processes including neuroinflammation …

As blood–brain barrier (BBB) disruption emerges as a common problem in the early stages
of neurodegenerative diseases, the crucial roles of barrier-type brain endothelial cells …

Alzheimer's disease (AD) is an aging-related form of dementia associated with the
accumulation of pathological aggregates of amyloid beta and neurofibrillary tangles in the …

Progression of Alzheimer's disease (AD) entails deterioration or aberrant function of multiple
brain cell types, eventually leading to neurodegeneration and cognitive decline. Defining …

The blood–brain barrier (BBB) is a unique and selective feature of the central nervous
system's vasculature. BBB dysfunction has been observed as an early sign of Alzheimer's …